This review offers a critical narrative evaluation of emerging evidence that sodium-glucose co-transporter-2 (SGLT2) inhibitors exert nephroprotective effects in people with type 2 diabetes. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.